Biotech Analysts focus on an update on Mirati on an Analyst/Industry conference call to be held on December 8.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- Mirati Therapeutics price target lowered to $84 from $110 at Piper Sandler
- Mirati adagrasib plus PD1 combo efficacy below expectations, says BofA
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- Mirati trial continuation ’tilts the scale for a positive outcome,’ says Piper